Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diagnostic Performance of Novel Urine-Based mRNA Tests (Xpert and Urinary Metabolomics Markers Assay) for Bladder Cancer Detection in Patients with Hematuria

Diagnostic Performance of Novel Urine-Based mRNA Tests (Xpert and Urinary Metabolomics Markers... BACKGROUND:Hematuria is the most frequent presenting symptom in the vast majority of bladder cancer (BC) patients. The current recommended evaluation of hematuria includes cross sectional imaging and cystoscopy with possible high negative results, expensive costs and substantial patient burden.OBJECTIVES:To validate novel urine-based mRNA-dependant tests; Xpert test and urinary metabolomics assay (CRAT and SLC 25A20genes expression) for BC detection in patients with hematuria.METHODS:Patients presented with hematuria to our tertiary care hospital were evaluated by CT urogram and office white light cystoscopy with subsequent inpatient biopsy for positive findings. Voided precystoscopy urine samples were prospectively collected. Xpert test, assay of targeted urinary metabolomics and cytology, were performed. The tests characteristics presumably were calculated based on the ability to identify BC noninvasively.RESULTS:Between March 2018 and June 2019, 181 patients were included in the final analysis with mean (±SD) age 62 (±10) years with 168 (92.8%) males. Macroscopic hematuria was encountered in 153 (84.5%) patients with irritative bladder symptoms in 48 (26.5%) patients. BC was confirmed by cystoscopy/biopsy in 36 (19.9%) patients. The performance characteristics of Xpert alone (SN: 73%, SP: 83%, NPV: 92%, PPV: 52%) (AUC 0.84, 95% CI 0.75–0.93, p = 0.001), metabolomics assay alone (SN: 89%, SP: 93%, NPV: 97%, PPV: 78%) (AUC 0.91, 95% CI 0.85–0.98, p < 0.001) and combination of both test results (SN: 66%, SP: 98%, NPV: 92%, PPV: 97%) (AUC 0.83, 95% CI 0.74–0.93, p = 0.001) were notably superior to urine cytology (SN: 30%, SP: 84%, NPV: 83%, PPV: 33%) (AUC 0.58, 95% CI 0.47–0.69, p = 0.154) for BC prediction. Cystoscopy-negative patients (CNP) were followed-up for a median (range) 12 (2–19) months. Re-cystoscopy was done for 35 patients with persistent symptoms. BC was diagnosed in 6 patients. Xpert and urinary metabolomics results were observably positive in those 6 patients.CONCLUSION:Xpert test and assay of urinary metabolomics (CRAT and SLC 25A20 genes expression) have the potential for BC detection in hematuria patients. These non invasive urine based tests can help prioritization of the use of invasive diagnostic tests in systems with long waiting times. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bladder Cancer IOS Press

Diagnostic Performance of Novel Urine-Based mRNA Tests (Xpert and Urinary Metabolomics Markers Assay) for Bladder Cancer Detection in Patients with Hematuria

Download PDF
10 pages

Loading next page...
 
/lp/ios-press/diagnostic-performance-of-novel-urine-based-mrna-tests-xpert-and-32ovB4V4gR

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2020 © 2020 – IOS Press and the authors. All rights reserved
ISSN
2352-3727
eISSN
2352-3735
DOI
10.3233/BLC-200318
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND:Hematuria is the most frequent presenting symptom in the vast majority of bladder cancer (BC) patients. The current recommended evaluation of hematuria includes cross sectional imaging and cystoscopy with possible high negative results, expensive costs and substantial patient burden.OBJECTIVES:To validate novel urine-based mRNA-dependant tests; Xpert test and urinary metabolomics assay (CRAT and SLC 25A20genes expression) for BC detection in patients with hematuria.METHODS:Patients presented with hematuria to our tertiary care hospital were evaluated by CT urogram and office white light cystoscopy with subsequent inpatient biopsy for positive findings. Voided precystoscopy urine samples were prospectively collected. Xpert test, assay of targeted urinary metabolomics and cytology, were performed. The tests characteristics presumably were calculated based on the ability to identify BC noninvasively.RESULTS:Between March 2018 and June 2019, 181 patients were included in the final analysis with mean (±SD) age 62 (±10) years with 168 (92.8%) males. Macroscopic hematuria was encountered in 153 (84.5%) patients with irritative bladder symptoms in 48 (26.5%) patients. BC was confirmed by cystoscopy/biopsy in 36 (19.9%) patients. The performance characteristics of Xpert alone (SN: 73%, SP: 83%, NPV: 92%, PPV: 52%) (AUC 0.84, 95% CI 0.75–0.93, p = 0.001), metabolomics assay alone (SN: 89%, SP: 93%, NPV: 97%, PPV: 78%) (AUC 0.91, 95% CI 0.85–0.98, p < 0.001) and combination of both test results (SN: 66%, SP: 98%, NPV: 92%, PPV: 97%) (AUC 0.83, 95% CI 0.74–0.93, p = 0.001) were notably superior to urine cytology (SN: 30%, SP: 84%, NPV: 83%, PPV: 33%) (AUC 0.58, 95% CI 0.47–0.69, p = 0.154) for BC prediction. Cystoscopy-negative patients (CNP) were followed-up for a median (range) 12 (2–19) months. Re-cystoscopy was done for 35 patients with persistent symptoms. BC was diagnosed in 6 patients. Xpert and urinary metabolomics results were observably positive in those 6 patients.CONCLUSION:Xpert test and assay of urinary metabolomics (CRAT and SLC 25A20 genes expression) have the potential for BC detection in hematuria patients. These non invasive urine based tests can help prioritization of the use of invasive diagnostic tests in systems with long waiting times.

Journal

Bladder Cancer – IOS Press

Published: Sep 21, 2020

References

  • The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice
    Bruyninckx
  • The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria
    Gonzalez
  • Evaluation of Hematuria in a Large Public Health Care System
    Ghandour
  • Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer
    Ramirez
  • Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline
    Davis
  • Canadian guidelines for the management of asymptomatic microscopic hematuria in adults
    Wollin
  • The economics of bladder cancer: costs and considerations of caring for this disease
    Svatek
  • Asymptomatic Microscopic Hematuria-Rethinking the Diagnostic Algorithm
    Subak
  • Epidemiology and risk factors of urothelial bladder cancer
    Burger
  • Bladder tumor markers: from hematuria to molecular diagnostics–where do we stand?
    Shirodkar
  • Urine markers for detection and surveillance of non-muscle-invasive bladder cancer
    Tilki
  • Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma
    Darling
  • Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance
    Pichler
  • Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer
    Valenberg
  • Bladder cancer determination via two urinary metabolites: a biomarker pattern approach
    Huang
  • Diagnosis of bladder cancer and prediction of survival by urinary metabolomics
    Jin
  • Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls
    Kim
  • The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology
    Barkan
  • Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection
    Wallace
  • Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines
    Schmitz-Drager
  • The Investigation of Hematuria
    Bolenz
  • Who Should Be Investigated for Haematuria?
    Tan
  • Adverse effects of cystoscopy and its impact on patients’ quality of life and sexual performance
    Stav
  • Incidence of Adverse Contrast Reaction Following Nonintravenous Urinary Tract Imaging
    Blackwell
  • Delays in the diagnosis and initial treatment of bladder cancer in Western Australia
    McCombie
  • Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer
    Yafi
  • Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus
    Schmitz-Drager
  • The need for repeated urological evaluation in low-risk patients with microscopic hematuria after negative diagnostic work-up
    Pichler